The Learning Curve of Transurethral Holmium Laser Enucleation of the Prostate, Prospective Assessment
1 other identifier
interventional
200
1 country
1
Brief Summary
Despite the high-quality evidence supporting the safety and efficacy of Holmium laser enucleation of the prostate (HOLEP), wide adoption of the procedure is hindered by learning difficulties. Veil-sparing HOLEP was popularized with a standardized approach to learning. Prospective multicenter assessment of the learning curve of HoLEP through a novel technique with structured learning protocol. Learning outcome measures will be assessed against time and number of performed cases of new learners in a multicenter study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Aug 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2023
CompletedFirst Submitted
Initial submission to the registry
September 10, 2023
CompletedFirst Posted
Study publicly available on registry
September 15, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedSeptember 15, 2023
September 1, 2023
2 years
September 10, 2023
September 10, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
time to plateau in enucleation effeminacy
time needed to reach a fixed rate of grams of prostate tissue removed per unit time (minute)
one year
Study Arms (1)
Holmium laser enculeation of the prostate
EXPERIMENTALveil-sparing Holmium laser enucleation of the prostate
Interventions
Holmium laser enucleation of the prostate using the veil-sparing technique
Eligibility Criteria
You may qualify if:
- Patients with prostate volume (≥40 cc) who are indicated for transurethral surgery for the BPO.
You may not qualify if:
- Patients with IPSS \<13.
- Patients with Qmax \>15 mL/s.
- Presence of urethral stricture.
- Patients with neurogenic bladder.
- Patients with prostate cancer.
- Patients with previous prostate surgery.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Urology and nephrology center
Al Mansurah, DK, 35516, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Urology
Study Record Dates
First Submitted
September 10, 2023
First Posted
September 15, 2023
Study Start
August 1, 2023
Primary Completion
August 1, 2025
Study Completion
December 1, 2025
Last Updated
September 15, 2023
Record last verified: 2023-09